Skip to content
10-Q

Quarterly Report

Lantern Pharma Inc. LTRN

0001641172-25-010547

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 9, 2025 10.78M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $6.38M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $7.51M
Current Liabilities Q1 2025 · Mar 31, 2025 $4.29M
Current Liabilities Q1 2025 · Dec 31, 2024 $4.33M
Total Liabilities Q1 2025 · Mar 31, 2025 $4.32M
Total Liabilities Q1 2025 · Dec 31, 2024 $4.38M
Current Assets Q1 2025 · Mar 31, 2025 $20.82M
Current Assets Q1 2025 · Dec 31, 2024 $25.25M
Total Assets Q1 2025 · Mar 31, 2025 $21.1M
Total Assets Q1 2025 · Dec 31, 2024 $25.57M
Shares Diluted Q1 2025 · Mar 31, 2024 10.74M sh
Capex Q1 2025 · Mar 31, 2024 $2.22K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$3.07M
Stockholders Equity Q1 2025 · Mar 31, 2024 $35.77M
Stockholders Equity Q1 2025 · Dec 31, 2023 $40.91M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.51
Eps Basic Q1 2025 · Mar 31, 2024 −$0.51
Sga Expense Q1 2025 · Mar 31, 2024 $1.48M
Rd Expense Q1 2025 · Mar 31, 2024 $4.25M
Net Income Q1 2025 · Mar 31, 2024 −$5.44M
Operating Income Q1 2025 · Mar 31, 2024 −$5.73M